title: Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
abstract: SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular riskhttp://ow.ly/p6Is300ffoc.
authors.affiliation: Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; Lung Clinic Immenhausen, Immenhausen, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Andreas
authors.affiliation: Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
authors.forename: Christer
authors.initials: C
authors.lastname: Janson
authors.affiliation: University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases, Groningen, The Netherlands.
authors.forename: Maarten
authors.initials: M
authors.lastname: van den Berge
authors.affiliation: Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Lies
authors.initials: L
authors.lastname: Lahousse